AR129994A1 - SOLUCIONES FARMACÉUTICAS DE ANTICUERPOS ANTI-N3PGLU Ab Y USOS DE ESTAS - Google Patents

SOLUCIONES FARMACÉUTICAS DE ANTICUERPOS ANTI-N3PGLU Ab Y USOS DE ESTAS

Info

Publication number
AR129994A1
AR129994A1 ARP230101919A ARP230101919A AR129994A1 AR 129994 A1 AR129994 A1 AR 129994A1 AR P230101919 A ARP230101919 A AR P230101919A AR P230101919 A ARP230101919 A AR P230101919A AR 129994 A1 AR129994 A1 AR 129994A1
Authority
AR
Argentina
Prior art keywords
n3pglu
pharmaceutical solutions
antibodies
antibodies pharmaceutical
solutions
Prior art date
Application number
ARP230101919A
Other languages
English (en)
Spanish (es)
Inventor
Vincent Corvari
Nicole H Durbin
Anant Navanithan Sharma
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR129994A1 publication Critical patent/AR129994A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ARP230101919A 2022-07-21 2023-07-21 SOLUCIONES FARMACÉUTICAS DE ANTICUERPOS ANTI-N3PGLU Ab Y USOS DE ESTAS AR129994A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263369033P 2022-07-21 2022-07-21

Publications (1)

Publication Number Publication Date
AR129994A1 true AR129994A1 (es) 2024-10-23

Family

ID=87576063

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230101919A AR129994A1 (es) 2022-07-21 2023-07-21 SOLUCIONES FARMACÉUTICAS DE ANTICUERPOS ANTI-N3PGLU Ab Y USOS DE ESTAS

Country Status (18)

Country Link
EP (1) EP4558166A1 (fr)
JP (1) JP2025525587A (fr)
KR (1) KR20250037554A (fr)
CN (1) CN119604302A (fr)
AR (1) AR129994A1 (fr)
AU (1) AU2023309007A1 (fr)
CA (1) CA3261418A1 (fr)
CL (1) CL2025000145A1 (fr)
CO (1) CO2025000508A2 (fr)
CR (1) CR20250023A (fr)
DO (1) DOP2025000005A (fr)
IL (1) IL318102A (fr)
JO (1) JOP20250013A1 (fr)
MA (1) MA71558A (fr)
MX (1) MX2025000820A (fr)
PE (1) PE20250785A1 (fr)
TW (1) TW202421188A (fr)
WO (1) WO2024020470A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3042917T3 (pl) * 2010-08-12 2018-07-31 Eli Lilly And Company Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie

Also Published As

Publication number Publication date
PE20250785A1 (es) 2025-03-14
DOP2025000005A (es) 2025-02-28
CO2025000508A2 (es) 2025-02-04
WO2024020470A1 (fr) 2024-01-25
JP2025525587A (ja) 2025-08-05
JOP20250013A1 (ar) 2025-01-21
CA3261418A1 (fr) 2024-01-25
AU2023309007A1 (en) 2025-01-30
CR20250023A (es) 2025-02-17
CN119604302A (zh) 2025-03-11
MA71558A (fr) 2025-05-30
TW202421188A (zh) 2024-06-01
MX2025000820A (es) 2025-03-07
IL318102A (en) 2025-02-01
KR20250037554A (ko) 2025-03-17
EP4558166A1 (fr) 2025-05-28
CL2025000145A1 (es) 2025-05-30

Similar Documents

Publication Publication Date Title
BR0209777A (pt) Formulações lìquidas estáveis
GT200900268A (es) Polipeptidos de factor vii modificados y usos de los mismos .
PA8479201A1 (es) Derivados del acido hidroxi-pipecolato hidroxamico
JOP20240288A1 (ar) أجسام مضادة لـ ror1 ومتقارنات الأجسام المضادة، تركيبات تحتوي على أجسام مضادة لـ ror1 أو متقارنات الأجسام المضادة، وطرق تصنيع واستخدام الأجسام المضادة لـ ror1 ومتقارنات الأجسام المضادة
RU2011115406A (ru) Новые пиримидиновые производные и их применение в терапии, а также применение пиримидиновых производных в изготовлении лекарственного средства для предупреждения и/или лечения болезни альцгеймера
BRPI0518101A (pt) métodos de produção e sìntese de composições nanoparticuladas, composições obtidas e seu uso
ATE407928T1 (de) Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
BRPI0410684A (pt) uso de um peptìdio conjugado a uma proteìna que age como um imunógeno para a produção de anticorpos capazes de reconhecer especificamente qualquer uma das variantes predominantes do peptìdeo beta amilóide aß40 e aß42 na preparação de um medicamento para a prevenção e/ou o tratamento de uma doença e uso de um anticorpo ou um fragmento ativo ou o derivado de um anticorpo que reconhece especificamente qualquer uma das variantes predominantes do peptìdio beta amilóide, aß40 e aß42, na preparação de um medicamento para prevenção e/ou tratamento de uma doença
ES2182107T3 (es) Uso en una composicion de un extracto de al menos una labiada del genero rosmarinarus, cultivado in vitro.
MX9705349A (es) Anticuerpo monoclonal 1a7 y su uso para el tratamiento de melanona y carcinoma de celulas pequeñas.
JOP20190155B1 (ar) مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
BRPI0517500B8 (pt) composto, uso de uma composição, composição farmacêutica, composição cosmética, usos não-terapêuticos de uma composição cosmética e processo cosmético para melhorar a aparência da pele
AR029619A1 (es) Vacuna
ES2156107T3 (es) Un fgf-4 no glicosilado y composiciones que lo contienen.
EA201001288A1 (ru) Лечение гипертонии 25-гидроксивитамином d3
AR057239A1 (es) Inmunoglobulinas
BR0311866A (pt) Composições de saponinas ou sapogeninas para terapia de câncer
AR129994A1 (es) SOLUCIONES FARMACÉUTICAS DE ANTICUERPOS ANTI-N3PGLU Ab Y USOS DE ESTAS
WO2023081194A3 (fr) Méthodes de traitement de la maladie d'alzheimer
JOP20250172A1 (ar) مُقترنات الأدوية والأجسام المضادة لـ cd70
MX2022006674A (es) Composiciones de celulas t reguladoras (treg) y metodos para tratar enfermedades neurodegenerativas.
MX2021015292A (es) Interacciones terapeuticas de leucometiltioninio.
BR112021016795A8 (pt) Administração de inibidor de enzima de ativação de sumo e inibidores de checkpoint
CL2023003209A1 (es) Composición farmacéutica de pembrolizumab y su uso